Impact of Lower Urinary Tract Symptoms and Depression on Health-Related Quality of Life in Older Adults

Song, Hyo Jeong; Han, Mi Ah; Kang, Hyung Chang; Park, Kyung Suk; Kim, Kwang Sung; Kim, Mi Kyung; Kang, Jina; Park, Eunok; Hyun, Mi Yeul; Kim, Chul Soo

doi:10.5213/inj.2012.16.3.132

Cited by 19 publications

(20 citation statements)

References 30 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With OAB wet, a person may be unable to stop leakage before reaching the toilet. It has significant effects on health-related QoL in both men and women, affecting their ability to work, physical activity, sexual function, and sleep [141516]. When we treated the female patients with OAB wet, long-term maintenance of antimuscarinic agents should be recommended based on the result from the present study.…”

Section: Discussionmentioning

confidence: 96%

Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment

et al. 2017

View full text Add to dashboard Cite

PurposeTo identify incidence and risk factors of recurrence after discontinuation of successful antimuscarinic therapy in patients with overactive bladder (OAB).Materials and MethodsThis was a prospective, multicenter trial. Patients who had antimuscarinic agents for more than 12 weeks and showed successful response were enrolled. Successful response was defined as answering 'benefit' for patient perception of treatment benefit and answer lesser than 3 points in patient's perception of bladder condition (PPBC). The enrolled patients discontinued the antimuscarinics, and we evaluated their recurrence with PPBC and OAB symptom score (OABSS) at 1, 3, 6, and 12 months. Primary purpose was to identify the recurrence rate and secondary purpose was to reveal risk factors.ResultsFour hundred forty-one patients enrolled and 371 patients completed 6-month follow-up. The enrolled patients showed 1.6 points in PPBC, 2.9 points in OABSS and 1.4 points in IPSS (quality of life) which represented successful response after using antimuscarinics. The cumulative rates of recurrence were 25.6%, 42.3%, and 52.2% at 1, 3, 6 months, respectively. Among 177 patients who did not show recurrence at 6 months, 41 patients were followed up and 4 patients of the 41 patients (9.7%) showed recurrence at 12 months. On univariate and multivariate analyses of recurrence, OAB wet was the risk factor for recurrence after 6 months of discontinuation.ConclusionsDiscontinuation of antimuscarinic therapy after successful treatment resulted in high recurrence rate with time and OAB wet was the independent risk factor for recurrence.

show abstract

Section: Discussionmentioning

confidence: 96%

Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment

et al. 2017

View full text Add to dashboard Cite

show abstract

“…For example, LUTS patients with comorbid depression had poorer HRQOL than LUTS patients without comorbid depression . A study on Korean males and females with LUTS found that those with more severe depression had poorer HRQOL . Quek found that depressive and anxiety symptoms were factors associated with the HRQOL of patients with LUTS .…”

Section: Introductionmentioning

confidence: 99%

Mental Health Mediating the Relationship Between Symptom Severity and Health‐Related Quality of Life in Patients with Lower Urinary Tract Symptoms

Choi

Lam

Chin

2015

LUTS

View full text Add to dashboard Cite

show abstract

“…Other studies have shown that LUTS can negatively impact patients’ health‐related quality of life (HRQoL) . A cross‐sectional survey of 1 627 men aged 40–79 years found 51% of men with BPH reported interference with at least one daily living activity due to urinary dysfunction, compared with 28% of men without BPH .…”

Section: Introductionmentioning

confidence: 99%

Responder and health‐related quality of life analyses in men with lower urinary tract symptoms treated with a fixed‐dose combination of solifenacin and tamsulosin oral‐controlled absorption system: results from the NEPTUNE study

et al. 2015

View full text Add to dashboard Cite

Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study ObjectiveTo evaluate the effect of a fixed-dose combination (FDC) of solifenacin and an oral-controlled absorption system (OCAS TM ) formulation of tamsulosin (TOCAS) on healthrelated quality of life (HRQoL) in men with lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). Patients and methodsMen with moderate-to-severe storage symptoms and voiding symptoms were treated for 12 weeks with a FDC of solifenacin 6 or 9 mg plus TOCAS (0.4 mg), TOCAS monotherapy (0.4 mg) or placebo in a randomised, doubleblind study (NEPTUNE). The co-primary endpoints were Total Urgency Frequency Score (TUFS) and total International Prostate Symptom Score (IPSS). HRQoL was assessed by several secondary endpoints: IPSS QoL index, overactive bladder questionnaire (OAB-q), and Patient Global Impression (PGI) scale. The correlation between symptom improvement (TUFS) and HRQoL was assessed by Spearman rank correlation coefficients. Single and double responder analyses, using subjective and objective measures, were also performed. ResultsIn the responder analyses, men treated with a FDC of solifenacin 6 mg plus TOCAS consistently had significantly improved outcomes compared with placebo (8/8 responder analyses performed) and TOCAS (6/8 responder analyses performed). There was a significant correlation (P < 0.001) between the reduction in TUFS and the improvement in HRQoL defined by IPSS QoL score, OAB-q symptom bother score, PGI overall bladder symptoms and PGI general health. ConclusionsIn men with LUTS/BPH who have moderate-to-severe storage symptoms and voiding symptoms, the reduction in symptoms with a once-daily FDC of solifenacin and TOCAS was associated with consistent patient-relevant improvements in HRQoL compared with placebo and TOCAS monotherapy.Keywords benign prostatic hyperplasia, health-related quality of life, lower urinary tract symptoms, solifenacin, tamsulosin

show abstract

Impact of Lower Urinary Tract Symptoms and Depression on Health-Related Quality of Life in Older Adults

Cited by 19 publications

References 30 publications

Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment

Incidence and risk factors of recurrence of overactive bladder symptoms after discontinuation of successful medical treatment

Mental Health Mediating the Relationship Between Symptom Severity and Health‐Related Quality of Life in Patients with Lower Urinary Tract Symptoms

Responder and health‐related quality of life analyses in men with lower urinary tract symptoms treated with a fixed‐dose combination of solifenacin and tamsulosin oral‐controlled absorption system: results from the NEPTUNE study

Contact Info

Product

Resources

About